Eupraxia Pharmaceuticals Insider Trading
TSX EPRX
4
All Trades
3
Significant
1
Notable
0
Clusters
0
Repeat
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals | Pimstone, Simon | Chairman | 27-Mar-26 | 44,678 | SI | ||||
| Eupraxia Pharmaceuticals | Freedman, Joseph | Director | 18-Mar-26 | 337,910 | NT | ||||
| Eupraxia Pharmaceuticals | Brennan, Paul | Chief Development Officer | 24-Nov-25 | 43,500 | SI | ||||
| Eupraxia Pharmaceuticals | Freedman, Joseph | Director | 16-Jun-25 | 45,400 | SI |
Stock Chart
Related Companies to Explore
Company Info
Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally-acting microsphere-based drug formulations for the treatment of musculoskeletal pain and inflammation. The company’s lead program EP-104IAR is being developed for the treatment of knee osteoarthritis pain, offering an extended-release formulation designed for single-injection quarterly dosing. Headquartered in Victoria, British Columbia, Eupraxia is advancing its pipeline through clinical trials. Listed on the Toronto Stock Exchange under the ticker EPRX.
Don’t miss today’s trades
Full access to real-time insider buying data — $8.25/mo, billed annually. Cancel anytime.